Related Experiment Video
Updated: Sep 10, 2026
Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
Published on: December 8, 2023
Fresh (Non-cryopreserved) autologous stem cell transplantation in multiple myeloma: Faster engraftment and reduced
Merve Kakci1, Osman Can Öztürk1, Ömer Şeker1
1Department of Hematology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.
Background:
Cryopreserved autologous hematopoietic stem cell transplantation using dimethyl sulfoxide is standard in multiple myeloma but it is associated with infusion-related toxicity and high cost. This study aimed to evaluate the feasibility, safety, and outcomes of dimethyl sulfoxide-free, fresh (non-cryopreserved) autologous stem cell transplantation in multiple myeloma patients at a single tertiary center.
Methods:
A retrospective analysis was conducted in 40 multiple myeloma patients who underwent transplantation using freshly collected, non-cryopreserved peripheral blood stem cells between 2023 and 2025 at Dokuz Eylül University Hospital. Peripheral blood stem cells were infused within 72 h after collection without cryopreservation. Engraftment kinetics, toxicity, and length of hospital stay were assessed descriptively.
Results:
All patients achieved hematopoietic engraftment (100%). Median neutrophil and platelet engraftment occurred at nine (range: 6-14) and 11 days (range: 7-16), respectively and the median hospitalization was 13 days. No infusion-related adverse events or grade 3-4 mucositis were observed. This approach eliminated dimethyl sulfoxide-related toxicity, reduced cryopreservation-related resource utilization and associated procedural costs.
Conclusion:
Fresh, dimethyl sulfoxide-free autologous stem cell transplantation in multiple myeloma is a safe, effective, and cost-efficient alternative to cryopreserved transplantation. It provides rapid engraftment, reduced hospitalization, and improved patient comfort, representing a practical model for modern transplant centers.
